Biomaterial Database

[Comparison of effects of systemic (intramuscular) and intrastriatal injections of D1-dopamine receptor blocker on motor behavior and postural adjustment in dogs]. 2008

K B Shapovalova, and Iu V Kamkina

The study is based on the concept (Shapovalova, 2000) that activation and blockade of various types of muscarine and dopamine receptors located at various outputs of neostriatum should have different effects on motor behavior. The goal of the study was comparison of effects of systemic and intrastriatal injections of a selective blocker of D1 dopamine receptors on motor behavior. Experiments were carried out on 5 dogs on a model of instrumental defensive reflex (IDR) connected with keeping a certain flexor posture. Performance of the experiments, recording, storage, and analysis of data were accomplished with aid of original programs for PC. Systemic (intramuscular) administration of the blocker of D1 dopamine receptors SCH23390 at a dose of 0.025 mg/kg led to a sharp decrease of the IDR amplitude and in most cases--to the complete refusal of its performance. First of all, the phasic component of the instrumental response was inhibited, the diagonal pattern of the postural adjustment being preserved. Bilateral microinjections into the dog neostriatum of the same blocker of D1 receptors at a dose of 0.1 and 1.0 g did not change the percent of correct solution of the instrumental task, but at the same time produced a great number of changes in motorics: latent period of response increased statistically significantly, in some cases its amplitude rose, phasity decreased, intersignal raisings of limbs ceased completely. The obtained data allow the following conclusions to be made. 1. Difference of effects of systemic and intrastriatal injections of SCH23390 seems to be due to that at its systemic administration, D1 receptors of other structures, not only of neostriatum, can also be blocked. 2. Effect of nigrostriatal dopaminergic system on neostriatum via D1 receptors is complex - activation of motor activity (projectional spine neurons of the direct pathway) and a weak modulation of mental process (large spineless cholinergic interneurons). 3. Regulation of movement and postural adjustment is realized along different efferent neostriatum outputs.

UI	MeSH Term	Description	Entries
D007273	Injections, Intramuscular	Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.	Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297	Male		Males
D008845	Microinjections	The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes.	Microinjection
D009043	Motor Activity	Body movements of a human or an animal as a behavioral phenomenon.	Activities, Motor,Activity, Motor,Motor Activities
D011187	Posture	The position or physical attitude of the body.	Postures
D003342	Corpus Striatum	Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE.	Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004285	Dogs	The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)	Canis familiaris,Dog
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D017447	Receptors, Dopamine D1	A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES.	Dopamine D1 Receptors,Dopamine-D1 Receptor,D1 Receptors, Dopamine,Dopamine D1 Receptor,Receptor, Dopamine-D1
D018492	Dopamine Antagonists	Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.	Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine